(ACTH) release from the pituitary, leading to increases in cortisol (corticosterone in rodents) secretion from the adrenal glands. CRH binds to two G-protein coupled receptors: CRH-R1 and CRH-R2 with CRH-R2 presenting with three splice variants of the same gene (CRH-R2a, CRH-R2b and CRH-R2c) Perrin et al. 1993; Lovenberg et al. 1995; Grigoriadis et al. 1996; Bale et al. 2002; ) . CRH-R1 is abundantly expressed in the cerebral cortex, cerebellum, medial septum and anterior pituitary , CRH-R2a is present in subcortical regions including the lateral septum and paraventricular and ventromedial nuclei of the hypothalamus, CRH-R2b is the predominant receptor expressed in the peripheral tissues, such as the heart, gastrointestinal tract, arterioles and muscle. CRH-R2c has recently been identified in the human brain in septum and hippocampus, with weaker but detectable expression in the amygdala, nucleus accumbens, midbrain, and frontal cortex Kostich et al. 1998; McCarthy et al. 1999; Gallagher et al. 2008) .
Knockout and anti-sense experiments suggest that CRH-R1 mediates the effects of CRH in regulating the HPA axis and anxiety-related behaviors (Heinrichs et al. 1997; Smith et al. 1998; Preil et al. 2001) . Mice deficient for CRH-R1 display a severe impairment of CRH-and stress-induced ACTH release from pituitary corticotropes, marked glucocorticoid deficiency, and reduced anxiety-like behaviors (Smith et al. 1998; Timpl et al. 1998; Muller et al. 2001) . Analyses of CRH-R2-deficient mice demonstrate that CRH-R2 plays a modulatory role in the stress response involving the maintenance of ACTH release during stress exposure and the return to basal levels of plasma corticosterone following the removal of stressors (Coste et al. 2000; Bale et al. 2002) .
CRH antagonists have been developed that inhibit CRH binding to its receptors and antagonize its actions in vivo and in vitro (Curtis et al. 1994; Gulyas et al. 1995) . Astressin (AST), a non-selective CRH-antagonist that blocks both CRH-R1 and CRH-R2 and is particularly potent at inhibiting the HPA axis (McCarthy et al. 1999; Spina et al. 2000; Zorrilla et al. 2003; Tu et al. 2007) . AST has been found to be particularly effective in reducing the stress response in relatively severe stressful situations (Spina et al. 2000) . A non-peptide CRH receptor antagonist, specific for CRH-R1, antalarmin (ANT), penetrated the blood-brain barrier and inhibited CRH binding in rat pituitary and brain regions (Webster et al. 1996) . When used acutely, ANT inhibited CRH-stimulated ACTH release (Webster et al. 1996) , and the conditioned fear response in rats (Deak et al. 1999) as well as stressed-related behaviors in rhesus monkeys (Habib et al. 2000) , but not the ACTH or corticosterone response to inescapable shock (Deak et al. 1999) . CRH-R2-selective peptide antagonists, antisauvagine-30 (Ruhmann et al. 1998 ) and astressin-2B (Rivier et al. 2002) have both been used to characterize the effects mediated specifically by the CRH-R2.
Three subtypes of vasopressin receptors (V 1a , V 2 and V 1b or V 3 ) have been cloned Morel et al. 1992; de Keyzer et al. 1996) . V 1a receptors are present in vascular and hepatic tissues and mediate the pressor response of AVP. V 2 receptors are present in the kidney and mediate the anti-diuretic properties of AVP. The pituitary vasopressin receptor, V 1b (also called V 3 ), is related to, but distinct from the V 1a receptor and mediates the AVP-induced secretion of ACTH at the corticotroph. An investigational compound produced by Sanofi-Aventis, SSR149415 (SSR), is a V 1b AVP receptor antagonist (Serradeil-Le Gal et al. 2002) and has been found to be effective in rodent models of anxiety and depression (Griebel et al. 2005; Hodgson et al. 2007) .
Some of the behavioral and addictive properties of nicotine appear related to its activation of the stress response that is mediated by the HPA axis (Gilbert 1979) . Acute nicotine administration elevates plasma ACTH and corticosterone in laboratory animals (Cam et al. 1979; Andersson et al. 1981; Lutfy et al. 2006) . When rats selfadminister nicotine in both response-contingent and response-independent paradigms, a rise in corticosterone is seen (Donny et al. 2000) . Additionally, cigarette smoking increases circulating cortisol in humans (Seyler et al. 1984; Pomerleau and Pomerleau 1990) . Nicotine acts centrally to stimulate ACTH release, rather than directly at the level of the pituitary (Matta et al. 1987) and CRH has been implicated as a mediator of this response, although this notion has not been proven (Matta et al. 1998; Rosecrans and Karin 1998) . Therefore, in this paper, we used selective and non-selective CRH-R antagonists to elucidate the role of each CRH receptors in the nicotineinduced activation of the HPA axis, as measured by increases in plasma corticosterone secretion. We also used SSR, an AVP V 1b antagonist, to study the role of AVP receptors in the nicotine-induced stimulation of corticosterone secretion. Furthermore, we determined the effect of a combination of an AVP V 1b antagonist with selective CRH R2 or non-selective CRH antagonists to elucidate interactions between the these receptors that might mediate the ability of nicotine to stimulate corticosterone secretion. For comparison, the effect of CRH-R and AVP-R antagonists was studied on CRH-and AVP-induced corticosterone secretion, respectively. AST, AST2b and CRH (human, rat) were purchased from Sigma/Aldrich (St Louis, MO, USA) and dissolved in saline (SAL) 1 h prior to intraperitoneal (i.p.) or subcutaneous (s.c.) administration. Antalarmin hydrochloride was a generous gift from George P. Chrousos, MD (University of Athens, previously at the National Institutes of Health) and dissolved in 70% ethanol which was then diluted 100-fold with SAL so that the final ethanol concentration was 0.7%. Injection of this concentration of ethanol compared with SAL did not affect corticosterone levels (O. Aimiuwu and T. C. Friedman, unpublished data). SSR149415 was generously supplied by SanofiAventis and dissolved in dimethylsulfoxide (DMSO) and was then diluted with SAL so the final DMSO concentration was 10%. Doses of ANT (Deak et al. 1999; Navarro-Zaragoza et al. 2010) , AST (Gulyas et al. 1995) and AST2b (Rivier et al. 2002; Broadbear et al. 2004) were based on the literature. There was no difference in corticosterone secretion following administration of SAL or 10% DMSO solution so the vehicle groups were combined, wherever appropriate.
Materials and methods
Chemicals ())-Nicotine ([)]-1-methyl-2-[3-pyridyl]-pyrrolidine),
Animals
Eight-week-old male C57BL/6J mice (25-28 g), obtained from The Jackson Laboratory (Bar Harbor, ME, USA), were group-housed in cages (n = 4 mice per cage) with bed o' cob ¼ inch rodent bedding (Newco Laboratory, Rancho Cucamonga, CA, USA) and kept under a 12-h light/12-h dark cycle (lights on at 07:00 hours and off at 19:00 hours) with free access to water and food. All experimental procedures were conducted in accordance with the guidelines of the National Institutes of Health for the proper use of laboratory animals and approved by the Institutional Animal Care and Use Committee at Charles R. Drew University.
Experimental procedures
Mice were brought to a soundproof testing room at 0800 and left undisturbed for 3 h to acclimatize to the procedure room. Injections (described below) began between 11:00 and 12:00 hours and were staggered so the time of killing occurred at 13:00 hours for each mouse. The time points and doses of each inhibitor (described below) were based on our pilot time-course and doseresponse studies and our previous study (Lutfy et al. 2006 ). Mice were killed by decapitation in a separate room from the mice receiving injections. Trunk blood was collected in ice-cold 1.5-mL vials containing 50 lL of 7% EDTA. Samples were then centrifuged at 4°C (11 752 g for 5 min), supernatants (300-600 lL) were collected and frozen at )80°C until assayed for corticosterone.
Experiment 1: the effect of ANT and AST on CRH-induced release of corticosterone Mice were treated with SAL or ANT (20 mg/kg, i.p.) followed by SAL or CRH (10 lg/kg, s.c.) 90 min later. In separate experiments, mice were treated with SAL or AST (0.3 mg/kg, i.p.) followed by SAL or CRH (10 lg/kg, s.c.) 30 min later. For all treated groups, mice were killed 15 min after SAL or CRH administration and trunk blood collected and processed as described above. We used this dose of CRH that was on the linear portion of the dose-response curve so that any increase in the level of corticosterone could be easily detected.
Experiment 2: the effect of SSR on AVP-induced secretion of corticosterone Mice were treated with SAL or SSR (10 mg/kg, i.p.) followed by SAL or AVP (10 lg/kg, i.p.) 20 min later. Mice were then killed 15 min after SAL or AVP administration, trunk blood collected and processed as described above.
Experiment 3: the effect of ANT and AST on nicotine-induced secretion of corticosterone Mice were treated with SAL or ANT (20 mg/kg, i.p.) followed by SAL or nicotine (1.0 mg/kg, s.c.) 90 min later. In separate experiments, mice were treated with SAL or AST (0.3 mg/kg, i.p.) followed by SAL or nicotine (1.0 mg/kg, s.c.) 30 min later. For all treated groups, mice were killed 15 min after SAL or nicotine administration, trunk blood collected and processed as described above. We selected the time and dose of nicotine from our prior paper in which we performed time-course and dose-response studies examining the effect of nicotine on corticosterone secretion (Lutfy et al. 2006 ).
Experiment 4: the effect of SSR alone and in combination with AST on nicotine-induced secretion of corticosterone Mice were treated with SAL, SSR (10 mg/kg, i.p.), AST (0.3 mg/ kg) or a combination of SSR and AST followed by SAL or nicotine (1.0 mg/kg, s.c.) 30 min later. Naïve mice did not receive any injections. Mice were killed 15 min after SAL or nicotine administration, trunk blood collected and processed as described above. The time of drug administration and the dose of each drug were based on our pilot and previous studies (Lutfy et al. 2006 ).
Experiment 5: the effect of AST2b alone or with SSR on nicotine-stimulated corticosterone secretion Mice were treated with SAL, SSR (10 mg/kg, i.p.), AST2b (0.3 mg/ kg) or a combination of SSR and AST2b followed by SAL or nicotine (1.0 mg/kg, s.c.) 30 min later. Mice were killed 15 min after SAL or nicotine administration, trunk blood collected and processed as described above. The time of drug administration and the dose of each drug were based on our pilot and previous studies (Lutfy et al. 2006) .
Plasma hormone assays
All plasma hormone concentrations were measured in duplicate by radioimmunoassay as previously described (Lutfy et al. 2006 ) and batch-processed, that is, all samples collected were assayed at once. All hormone values were on the linear portion of the standard curve for the assay. Plasma corticosterone levels (5 lL of serum per assay) were measured by rat/mouse corticosterone 3 H kit (MP Biomedicals, Costa Mesa, CA, USA). Cross-reactivity, variance and assay range is given in our prior paper (Lutfy et al. 2006) .
Statistical analyses
Data are expressed as the mean ± standard error of the mean (SEM). The data were analyzed using one-or two-way analysis of variance (ANOVA) followed by the Newman-Keuls or Bonferroni post hoc test for one-and two-way ANOVA, respectively, to reveal significant differences between various groups. A value of p < 0.05 was considered statistically significant.
Results
The effect of ANT or AST on CRH-induced corticosterone secretion Post hoc testing showed that CRH stimulated the secretion of corticosterone in VEH-pretreated animals (p < 0.001; compare VEH-CRH vs. VEH-SAL), an effect that was blocked by ANT (p < 0.001; compare ANT-CRH vs. VEH-CRH group). This result suggests that the CRH-induced secretion of corticosterone is likely mediated by the same receptor that is blocked by ANT, which is most likely CRH-R1. Figure 2 illustrates the effect of AST pre-treatment on CRH-stimulated secretion of corticosterone. A two-way ANOVA revealed a significant effect of pre-treatment, that is, AST versus. SAL (F 1,27 = 28.2; p < 0.0001), a significant effect of treatment, that is, CRH versus. SAL (F 1,27 = 18.8; p < 0.0002) and a significant interaction between the two factors (F 1,27 = 4.38; p < 0.05). Post hoc testing showed that CRH increased corticosterone secretion in VEH-pretreated animals (p < 0.0001; VEH-CRH vs. VEH-SAL group), an effect that was blocked in AST-pretreated mice (p < 0.001; AST-CRH vs. VEH-CRH group). This result suggests that blockade of both receptors may be essential for the complete inhibition of CRH-mediated corticosterone secretion.
The effect of SSR on AVP-stimulated secretion of corticosterone Figure 3 shows the effect of SSR pre-treatment on AVPstimulated secretion of corticosterone. A two-way ANOVA revealed a significant effect of treatment (F 1,20 = 11.0; p < 0.005), but no significant effect of pre-treatment (F 1,20 = 2.76; p > 0.05) and no significant interaction between the two factors (F 1,20 = 0.51; p > 0.05). Post hoc testing showed that AVP increased corticosterone secretion in VEH-pretreated mice (p < 0.05, compare VEH-SAL and VEH-AVP) and this response was attenuated by SSR pretreatment (compare SSR-SAL and SSR-AVP). The reduction in corticosterone levels by SSR following AVP did not reach significance compared with vehicle plus AVP (p > 0.05). SSR did not alter basal level of corticosterone (compare SSR-SAL vs. VEH-SAL group; p > 0.05). This result suggests that the V 1b AVP receptor may mediate the stimulatory action of AVP on corticosterone secretion.
The effect of ANT or AST on nicotine-stimulated secretion of corticosterone Figure 4 shows the effect of ANT pre-treatment on nicotinestimulated secretion of corticosterone. A two-way ANOVA Fig. 1 The effect of ANT on CRH-stimulated corticosterone secretion. Mice (n = 7-8 per group) were pre-treated with ANT (20 lg/kg, i.p.) or VEH (i.p.) (pretreatment is shown in the legend) and 90 min later injected with CRH (10 lg/kg, s.c.) or SAL (s.c.) (treatment is shown on the x-axis). Mice were killed 15 min later and trunk blood was collected and used for the measurement of corticosterone. ***p < 0.001 compared with VEH-SAL. Fig. 2 The effect of AST on CRH-mediated secretion of corticosterone. Mice (n = 7-10 per group) were pre-treated with AST (0.3 mg/ kg, i.p.) or VEH (i.p.) and 15 min later were injected with CRH (10 lg/ kg, s.c.) or SAL (s.c.). Mice were killed after an additional 15 min. Trunk blood was collected and used for the measurement of corticosterone. ***p < 0.001 compared with VEH-SAL. Fig. 3 The effect of SSR149415 (SSR) on AVP-mediated secretion of corticosterone. Mice (n = 6 per group) were pre-treated with SSR (10 mg/kg, i.p.) or VEH (i.p.) and 20 min later were injected with AVP (10 lg/kg, s.c.) or SAL (s.c.). Mice were killed after an additional 15 min. Trunk blood was collected and used for the measurement of corticosterone. *p < 0.05 compared with VEH-SAL.
revealed a significant effect of treatment (F 1,22 = 68.6; p < 0.0001), but no significant effect of pre-treatment (F 1,22 = 0.04; p > 0.05) and no significant interaction between the two factors (F 1,22 = 0.04; p > 0.05). Post hoc testing showed that nicotine increased corticosterone secretion in both VEH-and ANT-pretreated mice (p < 0.001; compare VEH-NIC vs. VEH-SAL group and ANT-NIC vs. ANT-SAL group). ANT did not alter basal level of corticosterone (compare ANT-SAL vs. VEH-SAL group; p > 0.05). This result suggests that CRH-R1 receptor alone does not mediate the stimulatory action of nicotine on corticosterone secretion. Figure 5 demonstrates the effect of AST pre-treatment on nicotine-stimulated secretion of corticosterone. A two-way ANOVA revealed a significant effect of pre-treatment (F 1,54 = 66.4; p < 0.0001), a significant effect of treatment (F 1,54 = 37.2; p < 0.0001) and a trend toward a significant interaction between the two factors (F 1,54 = 3.7; p = 0.06). Post hoc testing indicated that nicotine increased corticosterone secretion in both VEH-and AST-pretreated mice (compare VEH-NIC vs. VEH-SAL group and AST-NIC vs. AST-VEH group; p < 0.01 or better). Examining this figure carefully, although the level of corticosterone was lower in the AST-treated group following by nicotine compared with mice receiving SAL followed by nicotine (compare AST-NIC vs. VEH-NIC group; p < 0.01), AST alone also reduced basal corticosterone secretion (compare AST-SAL vs. VEH-SAL group; p < 0.001). Furthermore, the difference in corticosterone secretion, following nicotine in mice receiving AST (76 ng/mL obtained by subtracting the basal from nicotine-stimulated corticosterone levels for the AST-pretreated mice) was greater than the increase in corticosterone level following nicotine in mice receiving SAL (39 ng/mL, obtained by subtracting the basal from nicotine-stimulated corticosterone levels for the VEH-pretreated mice). Together, these results indicate that AST may alter the level of nicotinestimulated secretion of corticosterone via an inhibitory action on basal corticosterone level, but does not block the nicotinestimulated secretion of corticosterone per se.
The effect of SSR alone and in combination with AST on nicotine-induced corticosterone secretion Figure 6 depicts the effect of AST and SSR pre-treatment either alone or in combination on nicotine-stimulated Fig. 4 The effect of ANT on nicotine-induced corticosterone secretion. Mice (n = 5-8 per group) were treated with ANT (20 lg/kg, i.p.) or VEH (i.p.) followed, 90 min later, by nicotine (NIC; 1 mg/kg, sc) or SAL (s.c.). Mice were killed 15 min later and trunk blood was collected and used for the measurement of corticosterone. ***p < 0.001 compared with their respective SAL group. Fig. 5 The effect of AST on nicotine-stimulated corticosterone secretion. Mice (n = 14-15 per group) received AST (0.3 mg/kg, i.p.) or VEH (i.p.) followed, 15 min later, by nicotine (NIC; 1.0 mg/kg, sc) or SAL (s.c.). Mice were killed 15 min later and trunk blood was collected and used for measurement of corticosterone. # p < 0.05 compared with VEH-SAL group; **p < 0.01 versus VEH-SAL group; ***p < 0.001 versus AST-SAL group; ++ p < 0.01 versus VEH-NIC group. Fig. 6 The effect of AST or SSR alone or in combination on nicotinestimulated corticosterone secretion. Mice (n = 6-8 per group) received AST (0.3 mg/kg, i.p.), SSR (10 mg/kg, i.p.) either alone or in combination. Controls were injected with VEH (n = 8 mice; i.p.) or left untreated (naïve; n = 4 mice). Fifteen minutes later, mice received nicotine (NIC; 1 mg/kg, s.c.) or SAL (s.c.) and were killed 15 min later. Trunk blood was collected and used for the measurement of corticosterone. *p < 0.05, **p < 0.01, ***p < 0.001 versus VEH-SAL treated control group. VEH-NIC group; p < 0.001). However, as observed earlier (Fig. 5) , the effect of AST was likely caused by its ability to reduce corticosterone secretion induced by stress of injection (compare AST-SAL vs. VEH-SAL and notice the effect of stress: VEH-SAL vs. naïve group). However, the AVP antagonist SSR did not alter the response to injection (compare SSR-SAL vs. VEH-SAL group; p > 0.05) or the action of nicotine (compare SSR-NIC vs. VEH-NIC group; p > 0.05). However, the combination of SSR with AST significantly reduced the nicotine-stimulated corticosterone secretion and this response was significantly greater than the effect of AST or SSR alone (compare AST-SSR-NIC vs. AST-NIC or SSR-NIC; p < 0.001). This result suggests that nicotine exerts its stimulatory action on corticosterone secretion via both CRH and AVP receptors.
In pilot data, we found that DMSO (10%) alone did not significantly affect the level of corticosterone compared with saline-treated controls. Therefore, the data for the DMSO-SAL and SAL-SAL groups were combined (Fig. 6) . Corticosterone levels following DMSO +AST +NIC were similar to AST-NIC (data not shown).
The effect of AST2b alone or with SSR on nicotine-stimulated corticosterone secretion Figure 7 illustrates the effect of the CRH-R2 specific antagonist, AST2b, pre-treatment alone or with SSR on nicotine-stimulated secretion of corticosterone. One-way ANOVA revealed a significant effect of treatment (F 6,31 = 13.6; p < 0.0001). Post hoc testing showed that nicotine increased corticosterone secretion in VEH-treated mice (compare VEH-NIC vs. VEH-SAL group, p < 0.05); however, pre-treatment with AST2b and AST2b+SSR did not block the stimulation (compare VEH-NIC with AST2b-NIC and VEH-NIC with AST2b-SSR-NIC; p = NS). This result suggests that blocking both the CRH-R2 receptor and the V 1b AVP receptor is not sufficient to block the stimulatory action of nicotine on corticosterone secretion.
The effect of ANT, AST or AST2b on vehicle-stressstimulated secretion of corticosterone ANT pre-treatment did not reduce corticosterone secretion compared with VEH-treated mice in Figs 1 and 4 indicating that the secretion of corticosterone induced by stress of handling/injection does not proceed via CRH-R1. Similarly, AST2b pre-treatment did not affect this response ( Fig. 7 ; p = NS). In contrast, AST pre-treatment reduced corticosterone secretion compared with VEH-treated mice (Figs 5 and 6) but it did not achieve statistical significance level in one experiment although clear reduction was evident (Fig. 2) . When the data were combined, AST pre-treatment significantly reduced corticosterone levels (p < 0.001). Overall, these results suggest that the stimulation of corticosterone secretion induced via the stress of handling and injection most likely proceeds via activation of both CRH-R1 and CRH-R2 receptors.
Discussion
One of the many physiological effects of nicotine is the activation of the HPA axis with a resultant increase in secretion of ACTH and glucocorticoids. In rodents, acute nicotine administration elevates plasma ACTH and corticosterone (Cam et al. 1979; Andersson et al. 1981) . Chronic nicotine administration given by repeated injections leads to an increase in corticosteroid production, albeit at a lower level than acute administration (Cam and Bassett 1984; Fuxe et al. 1989; Caggiula et al. 1991) . Furthermore, nicotine withdrawal leads to anxiety and stress, both of which are powerful incentives to continue smoking or to trigger relapse in former smokers; this effect is likely mediated by CRH (Benowitz 2010) . In humans, cigarette smoking increases circulating cortisol (Wilkins et al. 1982; Seyler et al. 1984; Pomerleau and Pomerleau 1990) . We have previously shown that nicotine administration acutely increases the level of corticosterone in C57Bl/6 mice (Lutfy et al. 2006) . However, the underlying mechanisms of nicotine-stimulated secretion of corticosterone are not fully defined. Accordingly, in the current study we used CRH antagonists to define the mechanism of this stimulatory action of nicotine on corticosterone secretion. Given that activation of the HPA axis is primarily mediated by the release of CRH, we first assessed the role of CRH receptors in the action of nicotine.
Our results revealed that pre-treatment with ANT [a nonpeptide CRH-R1 receptor antagonist (Webster et al. 1996) ] blocked the CRH-evoked secretion of corticosterone. However, ANT pre-treatment did not block the nicotine-induced secretion of corticosterone, suggesting that nicotine increased corticosterone secretion via a receptor other than CRH-R1. We then used AST, which is known to antagonize both CRH-R1 and CRH-R2 (Gulyas et al. 1995; McCarthy et al. 1999; Spina et al. 2000; Zorrilla et al. 2003) and found that it blocked the ability of CRH to increase corticosterone secretion, but failed to block the stimulatory action of nicotine on corticosterone secretion. Although the level of nicotine-stimulated corticosterone secretion was significantly lowered in mice pre-treated with AST, a closer observation of the data suggest that this was due to AST decreasing the rise in corticosterone secretion associated with the stress of injection and therefore, AST-sensitive receptors do not mediate the nicotine-induced stimulation of corticosterone secretion. Furthermore, the CRH-R2 antagonist, AST2b also failed to alter nicotine-induced stimulation of corticosterone secretion. We then used the AVP V 1b receptor antagonist, SSR, and found that this drug, which reduced AVP-mediated corticosterone secretion, did not block nicotine-induced corticosterone secretion. However, in the presence of AST, SSR completely blocked nicotine-induced corticosterone secretion. We interpret these results as that when either the CRH receptor(s) or the AVP V 1b receptor is blocked, a compensatory pathway using the other receptor is utilized by nicotine to stimulate corticosterone secretion. Nevertheless, when both the CRH antagonist, AST, and the AVP V 1b receptor antagonist, SSR, were used together, nicotineinduced corticosterone secretion was completely blocked.
We are familiar with the work of Okada and colleagues (Okada et al. 2003) who administered CP-154,526, a CRH-R1 antagonist closely related to ANT, intracerebroventricularly to anesthetized rats and found that CP-154,526 blocked the nicotine-induced stimulation of corticosterone. However in that paper, the basal corticosterone levels were 247 ng/mL which went up to over 400 ng/mL following nicotine administration. These levels were superphysiologic and thus the role of CRH-R1 in regulating more physiological levels of corticosterone was unclear. However, the failure of CRH antagonists in this study to alter the nicotine-stimulated secretion of corticosterone was not due to the choice of the dose of these antagonists because both antagonists clearly blocked the effect of CRH and these doses have been used previously (Gulyas et al. 1995; Deak et al. 1999; Rivier et al. 2002; Broadbear et al. 2004; Navarro-Zaragoza et al. 2010) . Additionally, the lack of the response is not due to central versus peripheral effects of ANT because there is good evidence that ANT readily crosses the blood-brain barrier (Webster et al. 1996) .
The adrenal cortex expresses both CRH and nicotinic acetylcholine (Davila-Garcia et al. 2003) receptors. Thus, it is possible that nicotine stimulates hypothalamic CRH that then travels systemically to stimulate secretion of corticosterone from the adrenal cortex or that nicotine directly stimulates corticosterone release from the adrenal gland. We consider this unlikely as elegant experiments conducted over 30 years ago showed that hypophysectomy completely blocked the effect of nicotine on corticosterone (Cam et al. 1979) , suggesting that the nicotine-mediated secretion of corticosterone is mediated by the pituitary. CRH-R2, in addition to CRH-R1 is expressed in the pituitary , and thus, we suspect that the site of action of the nicotine-induced CRH is at the level of the pituitary. Our results are complicated by the finding that CRH-R1 null mice do not respond to CRH in terms of ACTH and corticosterone secretion . It is possible that nicotine-induced endogenous CRH has different biological actions compared with exogenous CRH and may have different sensitivity profile to CRH1 and CRH2 antagonism.
We found that AST, but not ANT or AST2b blocked the increase in corticosterone induced by handling and injection. Thus, it appears that CRH-R1 mediates the CRH-induced activation of corticosterone, while both CRH-R1 and CRH-R2 play an important role in corticosterone secretion induced by stress of handling and injection.
In conclusion, AST, but not ANT completely abolished CRH-evoked release of corticosterone. Neither AST nor ANT blocked nicotine-induced-corticosterone secretion. Similarly, SSR alone was without effect on nicotine-stimulated corticosterone secretion. However, the combination of AST and SSR completely abolished this action of nicotine. We conclude that nicotine-induced corticosterone secretion involves both CRH receptors as well as the AVP V 1b receptor because when the CRH receptor(s) is blocked, nicotine may induce its action via the alternative pathway utilizing the AVP V 1b receptor. Our findings suggest that pharmacological intervention to block the pleasurable effect of nicotine, which may be partially mediated by corticosterone, could involve the development of drug(s) that block both CRH and AVP V 1b receptors, while drugs that block one system alone are unlikely to be effective. Further studies are needed to determine whether the combination of these antagonists would alter the rewarding and addictive actions of nicotine.
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